HER2-positive gastric cancer.

摘要: Human epidermal growth factor receptor 2 (HER2) is involved in the pathogenesis and poor outcomes of several types cancer, including advanced gastric gastroesophageal junction cancer. Molecular-targeted drugs, such as trastuzumab, which prolong overall survival progression-free HER2-positive breast may also be beneficial patients with Several studies have examined this possibility, Trastuzumab for Gastric Cancer trial. In context, first part review provides an update on our knowledge HER2 detection prognostic relevance The second discusses results pivotal clinical trials that potential using trastuzumab to treat disease. This section summarizes been conducted or are underway determine optimal uses its use monotherapy continuation beyond disease progression. final future prospects other anti-HER2 lapatinib, emtansine, pertuzumab, treatment introduction led establishment a new entity, “HER2-positive cancer,” similar It expected more drugs will developed introduced into practice cancers,